Navigation Links
Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy
Date:7/26/2011

PHILADELPHIA, July 26, 2011 /PRNewswire-USNewswire/ -- The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania announces the launching of a first-of-its-kind interdisciplinary center focused on discovering novel treatments for orphan diseases. The Center will bring together, without institutional walls, all necessary approaches to attacking and treating orphan diseases: establishing dedicated research support facilities, translating findings into therapies, fostering targeted grant awards, and educating physicians and researchers.  

Formation of the new Penn Center for Orphan Disease Research and Therapy was catalyzed by a $10 million gift from an anonymous donor, whose vision matched that of Penn Medicine in developing treatments for these diseases.  The Center will fill a crucial need by providing the core laboratories, techniques, collaborative relationships, and expertise to lead an international, coordinated effort in the eradication of orphan diseases. Key among these resources is a state-of-the-art, robotically controlled drug screening laboratory that enables researchers from around the world to rapidly probe existing compound libraries for effective, orphan disease treatments.

Diseases are classified as orphan when they affect fewer than 200,000 people. However, as there are approximately 7,000 diseases now identified in this population, more than 25 million Americans are currently afflicted. Many of these diseases are caused by genetic mutations and are diagnosed in children. Research in many orphan diseases has lagged behind other major disease categories, such as diabetes and cardiovascular disease, in part because of a relative lack of technical expertise and funding mechanisms. Penn's Center will specifically address these needs.

"The research and development marketplace is not designed to optimally support research to develop the therapies so desperately needed for orphan diseases," explains Glen N. Gaulton, Ph.D., Executive Vice Dean and Chief Scientific Officer at the Perelman School. "Penn's new Center for Orphan Disease Research and Therapy will build not only strong collaborative relationships throughout Penn, but also with other leading academic medical centers, as well as public and private institutions -- all designed to translate innovative research into the clinic. There's simply nothing else like it."

"This is a wonderful example of philanthropy in action," says J. Larry Jameson, M.D., Executive Vice President for the Health System and Dean of the Perelman School of Medicine. "The Center will be a natural extension of Penn's expertise in orphan diseases, and this strategic investment will galvanize support for orphan disease research around the globe. I am proud that Penn Medicine is taking a clear leadership position in transforming the health of millions."

Jameson adds that he is delighted that his predecessor, former Perelman School Dean Arthur H. Rubenstein, MBBCh, has agreed to serve as Acting Director for the Center, while an international search is conducted for a permanent director.

http://www.med.upenn.edu/

CONTACT: Karen Kreeger
(215) 349 -5658
Karen.kreeger@uphs.upenn.edu


'/>"/>
SOURCE The Perelman School of Medicine at the University of Pennsylvania
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark
2. Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use
3. Metabolic Solutions Development Company Receives $773,000 From the Alzheimers Drug Discovery Foundation to Fund Phase 2a Trial
4. Unity Management Group, MCC Receives Authorization for Second Purchase Order From Bristol Meyers Squibb
5. TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards
6. Sorrento Therapeutics Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
7. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
8. China-Biotics, Inc. Receives NASDAQ Delisting Notification
9. UCSB professor receives Presidential Green Chemistry Challenge Award
10. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
11. Huda Y. Zoghbi, MD, Receives $500,000 Gruber Neuroscience Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):